SOFT 2004 Meeting Abstracts - Society of Forensic Toxicologists

Fl
COMPARISON OF SIMULATANEOUS CAMP AND BMBP MULTIPLE ANALYTE ENZYME
IMMUNOASSA Y REAGENTS WITH ABBOTT AND SYV A EMIT SINGLE ANALYTE
IMMUNOASSA Y REAGENT
Michael 1. Coyer*, Jill Mahoney and Dana Robosky, Clinical Laboratories, Inc, A LabCorp Company,
901 Keystone Industrial Park, Throop, PA 18512.
The development of drugs of abuse testing (DOA) has seen significant changes since the principals
competitive binding of Yalow and Solomon were adapted to DOA screening. The changes in the governing
regulations, the instrumentation and testing requirements has led to more emphasis being placed on turn
around times and cost of the test to the client. The many advances in antibody production have enhanced
the selectivity and specificity of screening tools much to the advantage ofthe laboratory and the client.
This investigator has begun the evaluation of a Multiple Analyte Enzyme Immunoassay (MAEl) products:
specifically, 1.) Cocaine-Amphetamine-Morphine-Phencyclidine (CAMP) and 2.) Barbiturate-Methadone­
Benzodiazepine-Propoxyphene (BMBP) recently approved by the FDA for use in the U.S. The design of
the dual reagent system CAMP and BMBP takes into account the values that are associated with the widely
accepted NIDN SAMHSA screening cut-offs. The reagents are designed to test the four (4) drugs in each
group in a single sampling. The resulting response of the instrumentation will be relative to a previously
determined cut-off value. Any result being above the threshold for a positive will be subjected to individual
analyte analysis. The samples giving no response will be considered negative and no further testing would
be performed. The reagent design is based on certain statistical data, specifically, > 90% of all urine drug
screens are negative. The design of the reagent system will enhance the turnaround time and costs
associated with testing operations while still holding the same high quality standards required ofthe testing
facilities.
This report will focus on the comparison of the MAEI reagents with previously tested samples. The
discussions will include comparisons ofthe MAEl with several reagent systems including, but not limited
to, Abbott (FPIA), and SYVA EMIT. The correlations of these analysis and discussion of the reagent
system will be presented. The preliminary testing has been completed and will be furthered after the
submission of this abstract to include statistics, cross reactivity and overall effectiveness in the testing for
drugs ofabuse.
Keywords: Multiple Analyte Enzyme Immunoassay, drugs ofabuse, turnaround time
Page 254